Thus, our in vitro results revealed that the chemotherapeutic agent doxorubicin can induce TGFβ signaling, promote EMT and generate cells with drug resistant stem cell phenotypes in murine breast cancer 4T1 cells, which could be reversed by the treatment with a TGFβ antagonist TβRI-KI. Here, TGFBR1 is linked to breast cancer.